A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine

Renal Failure

Volumn 20, Issue 6, 1998, Pages 749-762

  Bach, Peter H ^a   Berndt, William O ^b   Delzell, Elizabeth ^c   Dubach, Ulrich ^d   Finn, William F ^e   Fox, Johannes M ^f   Hess, Robert ^g   Michielsen, Paul ^h   Sandler, Dale P ⁱ   Trump, Benjamin ^j   Williams, Gary ^k  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d School of Medicine ^*

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MERZ PHARMACEUTICALS GMBH   (Germany)

^g UNIVERSITY OF BASEL   (Switzerland)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k AMERICAN HEALTH FOUNDATION   (United States)

more..

Author keywords

Acetaminophen; Acetylsalycilic acid; Analgesic nephropathy; Caffeine

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL; PHENACETIN;

DRUG ABUSE; DRUG FORMULATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 7844222458     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229809045173     Document Type: Review

References (113)

1. Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Abu D: Nonsteroidal anti-inflammatory drugs and renal failure. Lancet 1: 57-59, 1986.
2. Bach PH, Bridges JW: Chemically induced renal papillary necrosis and upper urothelial carcinoma. CRC Crit Rev Toxicol 15: 217-439, 1985.
3. Eknoyan G: Current status of chronic analgesic and nonsteroidal anti-inflammatory drug nephropathy. Curr Opin Nephrol Hypertens 3: 182-188, 1994.
4. Kincaid-Smith P: Analgesic Nephropathy. Aust NZ J Med 18: 251-255, 1988.
5. Murray TG, Goldberg M: Analgesic abuse and renal disease. Ann Rev Med 26: 537-550, 1975.
6. Murray TG, Goldberg M: Analgesic associated nephropathy in the USA: Epidemiologic Clinical and Pathogenic Features. Kidney Int 13: 64-71, 1978.
7. Buckalew VM Jr, Schey HM: Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine 65: 291-303, 1986.
8. Gonwa TA, Hamilton RW, Buckalew VM: Chronic renal failure and end-stage renal disease in northwest North Carolina. Importance of analgesic-associated nephropathy. Arch Intern Med 141: 462-465, 1981.
9. Maher JF: Analgesic nephropathy. Observations interpretations and perspective on the low incidence in America. Am J Med 76: 345-348, 1984.
10. Wing AJ, Brunner FP, Geerlings W, et al. Contribution of toxic nephropathies to end-stage renal failure in Europe: a report from the EDTA-ERA registry. Tox Lett 46: 281-292, 1989.
11. Elseviers MM, Bosteels V, Cambier P, de Paepe M, Godon JP, Lins R, Lomoy W, Matthys E, Moeremans C, Roose R, et al: Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: Results of the Belgian study. Nephrol Dial Transplant 7: 479-486, 1992.
12. Elseviers MM, de Schepper A, Corthouts R, Bosmans J-L, Cosyn L, Lins RL, Lomoy W, Matthys E, Roose R, Van Caesbroeck D, Waller I, Horackova M, Schwarz A, Svrcek P, Bonucchi D, Franek E, Morlans M, de Broe ME: High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 48:1316-1323, 1995.
13. Elseviers MM, Waller I, Nenoy D, Levora J, Matousovic K, Tanquerel T, Pommer W, Schwarz A, Keller E, Thieler H, et al: Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant 10: 808-814, 1995.
14. Bennett WM, DeBroe ME: Analgesic Nephropathy - a preventable renal disease. N Engl J Med 320: 1269-1271, 1989
15. Elseviers MM, de Broe ME: Is analgesic nephropathy still a problem in Belgium? Nephr Dial Transpl 2: 143-149, 1988.
16. de Broe ME, Elseviers MM: Analgesic nephropathy-still a problem? Nephron 64: 505-513, 1993.
17. de Broe ME Elseviers MM Bengtsson U, Mihatsch MJ, Molzahn M, Pommer W, Ritz E, Schwarz A: Analgesic Nephropathy. Nephrol Dial Transplant, 11: 2407-408, 1996.
18. Drukker W, Schwarz A, Vanherweghem JL: Analgesic nephropathy: an underestimated cause of end-stage renal disease. Int J Artif Organs 9: 219-246, 1986.
19. Duggin GG: Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 28: S39-47, 1996.
20. Henrich WL: Analgesic nephropathy. Am J Med Sci 295: 561-568, 1988.
21. Schwarz A: Analgesic-associated nephropathy. Klin Wochenschr 65: 1-16, 1987.
22. Henrich WL, Agodoa LE, Barrett B, Bennett WM, Blantz RC, Buckalew VM, D'Agati VD, de Broe ME, Duggin GG, Eknoyan G, et al: National Kidney Foundation Position Paper. Analgesics and the kidney. Am J Kidney Dis 27: 162-165, 1996.
23. Levy M: Adverse reactions to over-the-counter analgesics: an epidemiological evaluation. Agents Actions Suppl 25: 21-31, 1988.
24. Whelton A: Renal effects of over-the-counter analgesics. J Clin Pharmacol 5: 454-463, 1995.
25. Fox JM and members of the German Federal Drug Evaluation Committee. Kombinationsarzneimittel aus Paracetamol plus Acetylsalicylsāure - Nutzen und Risiken (Combination drugs of paracetamol and acetylsalicylic acid - Benefit and Risks). Der Schmerz 9: 273-285, 1995.
26. Bundesgesundheitsamt: Monographie: Acetylsalicylsāure plus Paracetamol in fixer Kombination. Bundesanzeiger 46, No. 88, 4975-4978, 1994.
27. Sawynok J, Yaksh TL: Caffeine as an analgesic adjuvant a review of pharmacology and mechanisms of action. Pharmacol Rev 45: 43-85, 1993.
28. Schachtel BP, Fillingim JM, Lane AC, Thoden WR, Baybutt RI: Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med 151: 733-737, 1991.
29. Koch GG, Amara IA, MacMillan J: Evaluation of alternative statistical models for crossover studies to demonstrate caffeine adjuvancy in the treatment of tension headache. J Biopharm Stat, 4: 347-410, 1994.
30. Migliardi JR, Armellino JJ, Friedman M, Gillings DB, Beaver WT: Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 56: 576-586, 1994.
31. Forbes JA, Beaver WT, Jones KF, Kehm CJ, Smith WK, Gongloff CM, Zeleznock JR, Smith JW: Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain. Clin Pharmacol Ther 49: 674-684, 1991.
32. Sawynok J: Pharmacological rationale for the clinical use of caffeine. Drugs 49: 37-50, 1995.
33. Thithapandha A: Effect of caffeine on the bioavailability and pharmacokinetics of aspirin. J Med Assoc Thai 72: 562-566, 1989.
34. Williams M, Jarvis MF: Adenosine antagonists as potential therapeutic agents. Pharmacol Biochem Behav 29: 433-411, 1988.
35. Barrett BJ: Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 28: S14-19, 1996.
36. Bennett WM, Henrich WL, Stoff JS: The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 28(Suppl 1): S56-62, 1996.
37. Elseviers MM, de Broe ME: Analgesic Nephropathy in Belgium is related to sales of particular analgesic mixtures. Nephrol Dial Transplant 9: 41-46, 1994.
38. Elseviers MM, de Broe ME: Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Am J Kidney Dis 28: S48-55, 1996.
39. Delzell E, Shapiro S: Commentary on the National Kidney Foundation position paper on analgesics and the kidney. Am J Kidney Dis 28: 783-785, 1996.
40. Delzell E, Shapiro S: A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine 77:102-21, 1998.
41. Dubach UC, Rosner B, Levy PS, Baumeler HR, Muller A, Peyer A, Ehrensperger T, Ettlin C: Epidemiological study in Switzerland. Kidney Int 13: 41-49, 1978.
42. Dubach UC: Analgesic nephropathy. Epidemiological studies and pharmacological investigations. Contrib Nephrol 16: 65-69, 1979.
43. Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity: 1968 to 1987. N Engl J Med, 324: 155-160, 1991.
44. Dubach UC, Rosner B, Sturmer T: Epidemiologic study of analgesic abuse: mortality study in 7275 working women: 1968-1987. Kidney Int 40: 728-733, 1991.
45. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD: End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 30: 17-23, 1990.
46. Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP: Analgesic use and chronic renal disease. N Engl J Med 320: 1238-1243, 1989.
47. Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Kumpel A, Borner K, Molzahn M: Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 9: 403-412, 1989.
48. McCredie M, Stewart JH, Mahony JF: Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin Nephrol 17: 134-140, 1982.
49. Steenland NK, Thun MJ, Ferguson CW, Port FK: Occupational and other exposures associated with male end stage renal disease: a case/control study. Am J Public Health 80:153-157, 1990.
50. Pemeger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen aspirin and nonsteroidal antiinflammatory drugs. N Engl J Med, 331: 1675-1679, 1994.
51. Sandler DP, Burr FR, Weinberg CR: Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115: 165-172, 1991.
52. Fox JM: No proof for a particular role of combination analgesics causing end-stage renal failure. [letter] Nephrol Dial Transplant 11: 2519-2520, 1996.
53. Nods LM, Elseviers MM, de Broe ME: Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy. a comparative study in France Sweden and Belgium. Nephrol Dial Transplant 10: 167-174, 1995.
54. Abbot PJ: Caffeine: a toxicological overview. Med J Aust 145: 518-520, 1986.
55. Kalow W: Caffeine and other drugs. Prog Clin Biol Res 214: 331-341, 1986.
56. Benowitz NL: Clinical pharmacology of caffeine. Annu Rev Med 41: 277-288, 1990.
57. Boyd EM Dolman M, Knight LM, Sheppard EP: The chronic oral toxicity of caffeine. Can J Physiol Pharmacol 43: 995-1007, 1965.
58. Boyd EM: The acute oral toxicity of caffeine. Tox Appl Pharmacol 1: 250-257, 1959.
59. Dalvi RR: Acute and chronic toxicity of caffeine: a review. Vet Hum Toxicol 28: 144-150, 1986.
60. Somani SM, Gupta P: Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Ther Toxicol, 26: 521-33, 1988.
61. Goldstein A, Kaizer S, Whitby O: Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee. Clin Pharmacol Ther 10: 489-497, 1969.
62. Lieberman HR, Wurtman RJ, Ernde GG, Coviella IL: The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 7: 315-320, 1987.
63. Pickworth WB: Caffeine dependence. Lancet 345: 1066, 1995.
64. Stephenson PE: Physiologic and psychotropic effects of caffeine on man. A review. J Am Diet Assoc 71: 240-247, 1977.
65. Hughes JR, Oliveto AH, Helzer JE, Higgins ST, Bickel WK: Should caffeine abuse dependence or withdrawal be added to DSM-IV and ICS 10? Am J Psychiatry 149: 33-40, 1992.
66. Fox JM and members of the German Federal Evaluation Committee: Coffein plus Analgetika - eine sinnvolle Kombination (Caffeine plus analgesics - a meaningful combination). Der Schmerz 2, 183-197, 1988.
67. Bundesgesundheitsamt: Monographie. Paracetamol plus Coffein in fixer Kombination. Bundesanzeiger 41, No. 209, 4778-4779, 1988.
68. Bundesgesundheitsamt: Monographie: Acetylsalicylsāure plus Coffein in fixer Kombination. Bundesanzeiger 46, No. 31, 1247-1249, 1994.
69. Greden JF, Victor BS, Fontaine P, Lubetsky M: Caffeine-withdrawal headache: a clinical profile. Psychosomatics 21: 411-413, 417-418, 1980.
70. Smith R: Caffeine withdrawal headache. J Clin Pharm Ther 12: 53-57, 1987.
71. Shorofsky MA, Lamm RN: Caffeine-withdrawal headache and fasting. N Y State J Med 77: 217-218, 1977.
72. Rainey JT: Headache related to chronic caffeine addiction. Tex Dent J 102: 29-30, 1985.
73. Murray RM: Genesis of analgesic nephropathy in the United Kingdom. Kidney Int 13: 50-57, 1978.
74. Hobi V, Ladewig D, Dubach UC, Miest P-Ch, Ehrensberger T: Analgesic abuse and personality characteristics. Int J Clin Pharmacol Biopharm 13: 36-41, 1976.
75. Murray RM: Personality factors in analgesic nephropathy. Psychol Med 4: 69-73, 1974.
76. Ladewig D, Miest PC, Dubach UC, Ettlin C, Hobi V: Use and abuse of non-narcotic analgesics. Drug Alcohol Depend 3: 435-442, 1978.
77. Appel RG, Bleyer AJ, McCabe JC: Case report analgesic nephropathy: a soda and a powder. Am J Med Sci 310: 161-166, 1995.
78. Michielsen P, de Schepper P: Analgesic nephropathy in Belgium: Confusion between prevalence and incidence. Am J Kidney Dis 28: 958-959, 1996.
79. Michielsen P, de Schepper P: Combination analgesic involvement in the pathogenesis of analgesic nephropathy. Am J Kidney Dis 28: 959-960, 1996.
80. Wilson DR, Gault MH: Declining incidence of analgesic nephropathy in Canada. Can Med Assoc J 127: 500-502, 1982.
81. Stewart JH, McCredie M, Disney APS, Mathew TH: Trends in incidence of end-stage renal failure in Australia: 1972-1991. Nephrol Dial Transplant 9: 1377-382, 1994.
82. Brunner FP, Selwood NH: End-stage renal failure due to analgesic nephropathy its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee Nephrol Dial Transplant 9: 1371-1376, 1994.
83. Segasothy M, Tong BK, Kamal A, Murad Z, Suleiman AB: Analgesic nephropathy associated with paracetamol. Aust N Z J Med 14: 23-26, 1984.
84. Segasothy M, Suleiman AB, Puvaneswary M, Rohana A: Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 50: 50-54, 1988.
85. Segasothy M, Samad SA, Zulfigar A, Bennett WM: Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis, 24: 17-24, 1994.
86. Segasothy M Thyaparan A Kamal A and Sivalingam S: Melfenamic acid nephropathy. Nephron 45: 156-157, 1987.
87. Segasothy M, Chin GL, Sia KK, Zulfiqar A, Samad SA: Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol 34: 162-165, 1995.
88. Caruana RJ, Semble EL: Renal papillary necrosis due to naproxen. J Rheumatol 11: 90-91, 1984.
89. Prescott LF: Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol, 10 Suppl 2: 291S-298S, 1980.
90. Joshi S, Zenser TV, Mattammal MB, Herman CA, Davis BB: Kidney metabolism of acetaminophen and phenacetin. J Lab Clin Med 92: 924-931, 1978.
91. Hinson JA: Reactive metabolites of phenacetin and acetaminophen: a review. Environ Health Perspect 49:71-79, 1983.
92. Baumeler HR, Ettlin C, Dubach UC, Ladewig D: [Trends in urinary analgesic excretion in a cohort observed from 1968 to 1975]. Soz Praventivmed 20: 242-243, 1975.
93. Burrell JH, Yong JL, MacDonald GJ: Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats. J Pathol 164: 329-338, 1991.
94. Burrell JH, Yong JL, MacDonald GJ: Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol. Pathology 23: 107-114, 1991.
95. Black HE. Renal toxicity of non-steroidal anti-inflammatory drugs. Toxicol Pathol 14: 83-90, 1986.
96. Bach PH, Thanh NTK: Renal papillary necrosis - 40 years on. Toxicol Pathol 26, 69-87, 1998.
97. Bach PH, Bridges JW: The role of prostaglandin synthase mediated metabolic activation of analgesics and non-steroidal anti-inflammatory drugs in the development of renal papillary necrosis and upper urothelial carcinoma. Prostagland Leuk Med 15: 251-274, 1984.
98. Lehmann H Hirsch U Bauer E Bauer M Greischel A Schmid J and Schneider P: Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. Arzneimittelforschung 46: 895-905, 1996.
99. Macklin AW, Szot RJ: Eighteen month oral study of aspirin phenacetin and caffeine in C57BL 6 mice. Drug Chem Toxicol 3: 135-163, 1980.
100. Mineshita S,Toyoshima A, Yazaki T: Influence of phenacetin and its metabolites on renal function Nippon Jinzo Gakkai Shi 31:629-633, 1989.
101. Champion-De-Crespigny P, Hewitson T, Birchall I, Kincaid-Smith P: Caffeine potentiates the nephrotoxicity of mefenamic acid on the rat renal papilla. Am J Nephrol 10: 311-315, 1990.
102. Hewitson TD, Champion de Crespigny PJ, Kincaid-Smith P: Caffeine potentiation of mefenamic acid-induced lesions in the rat renal medulla. J Pathol 165: 343-347, 1991.
103. Murray MD, Brater DC: Renal toxicity of the nonsteroidal anti-inflammatory drugs Annu Rev Pharmacol Toxicol 33: 435-65, 1993.
104. Carlton WW, Engelhardt JA: Experimental renal papillary necrosis in the Syrian hamster. Food Chem Toxicol 27: 331-340, 1989.
105. Duggjn GG Mechanisms in the development of analgesic nephropathy Kidney Int 18: 553-561, 1980.
106. Davis BB, Mattammal MB, Zenser TV: Renal metabolism of drugs and xenobiotics. Nephron 27: 187-196, 1981.
107. Smith BJ, Curtis JF, Eling TE: Bioactivation of xenobiotics by prostaglandin H synthase. Chem Biol Interact 79: 245-264, 1991.
108. Mohandas J, Duggin GG, Horvath JS, Tiller DJ: Regional differences in peroxidatic activation of paracetamol (acetaminophen)-mediated by cytochrome P-450 and prostaglandin endoperoxide synthetase in rabbit kidney. Res Commun Chem Pathol Pharmacol 34: 69-80, 1981.
109. Mohandas J, Duggjn GG, Horvath JS, Tiller DJ: Metabolic oxidation of acetaminophen (paracetamol)-mediated by cytochrome P-450 mixed function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney. Toxicol Appl Pharmacol 61: 252-259, 1981.
110. Ross D, Larsson R, Andersson B, Nilsson U, Lindquist T, Lindeke B, Moldeus P: The oxidation of p-phenetidine by horse radish peroxidase and prostaglandin synthase and the fate of glutathione during such oxidation. Biochem Pharmacol 34: 343-351, 1985.
111. Nelson SD, Dahlin DC, Rauckman RJ, Rosen GM: Peroxidase-mediated formation of reactive metabolites of acetaminophen. Mol Pharmacol 20: 195-199, 1981.
112. Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller DJ: Differential distribution of glutathione and glutathione-related enzymes in rabbit kidney. Biochem Pharmacol 33: 1801, 1984.
113. Boyd JA, Eling TE: Prostaglandin endoperoxide synthetase-dependent cooxidation of acetaminophen to intermediates which covalently bind in vitro to rabbit renal medullary microsomes. J Pharmacol Exp Ther 219: 659-664, 1981.